Viking Ther­a­peu­tics plans Ph2 tri­al for oral obe­si­ty drug af­ter pos­i­tive ear­ly-stage da­ta

Viking Ther­a­peu­tics tout­ed ear­ly-stage obe­si­ty da­ta show­ing its oral GLP-1/GIP dual ag­o­nist pro­duced 5.3% weight loss and few side ef­fects, send­ing the com­pa­ny’s stock …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER